Current treatment of symptomatic aortic stenosis in elderly patients: Do risk scores really matter after 80 years of age?

Aortic stenosis Remplacement valvulaire aortique chirurgical Remplacement valvulaire aortique percutané Risk assessment Risque opératoire Rétrécissement aortique Surgical aortic valve replacement Transcatheter aortic valve implantation

Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 08 03 2021
revised: 28 04 2021
accepted: 10 06 2021
pubmed: 4 10 2021
medline: 1 12 2021
entrez: 3 10 2021
Statut: ppublish

Résumé

According to the guidelines, surgical aortic valve replacement (SAVR) is recommended in patients at low surgical risk (EuroSCORE II<4%), whereas for other patients, the decision between transcatheter aortic valve implantation (TAVI) and surgery should be made by the Heart Team, with TAVI being favoured in elderly patients. The RAC prospective multicentre survey assessed the respective contributions of age and surgical risk scores in therapeutic decision making in elderly patients with severe symptomatic aortic stenosis. In September and October 2016, 1049 consecutive patients aged ≥ 75 years were included in 32 centres with on-site TAVI and surgical facilities. The primary endpoint was the decision between medical management, TAVI or SAVR. Mean age was 84±5 years and 53% of patients were female. The surgical risk was classified as high (EuroSCORE II>8%) in 18% of patients, intermediate (EuroSCORE II 4-8%) in 34% and low (EuroSCORE II≤4%) in 48%. TAVI was preferred in 71% of patients, SAVR in 19% and medical treatment in 10%. The choice of TAVI over SAVR was associated with older age (P<0.0001) and a higher EuroSCORE II (P=0.008). However, the weight of EuroSCORE II in therapeutic decision making markedly decreased after the age of 80 years. Indeed, 77% of patients aged ≥ 80 years were referred for TAVI, despite a low estimated surgical risk. The impact of risk scores depends strongly on age, and decreases considerably after 80 years, most patients being referred for TAVI, independent of their estimated surgical risk. Despite medical advancements, 10% of patients were still denied any intervention.

Sections du résumé

BACKGROUND BACKGROUND
According to the guidelines, surgical aortic valve replacement (SAVR) is recommended in patients at low surgical risk (EuroSCORE II<4%), whereas for other patients, the decision between transcatheter aortic valve implantation (TAVI) and surgery should be made by the Heart Team, with TAVI being favoured in elderly patients.
AIM OBJECTIVE
The RAC prospective multicentre survey assessed the respective contributions of age and surgical risk scores in therapeutic decision making in elderly patients with severe symptomatic aortic stenosis.
METHODS METHODS
In September and October 2016, 1049 consecutive patients aged ≥ 75 years were included in 32 centres with on-site TAVI and surgical facilities. The primary endpoint was the decision between medical management, TAVI or SAVR.
RESULTS RESULTS
Mean age was 84±5 years and 53% of patients were female. The surgical risk was classified as high (EuroSCORE II>8%) in 18% of patients, intermediate (EuroSCORE II 4-8%) in 34% and low (EuroSCORE II≤4%) in 48%. TAVI was preferred in 71% of patients, SAVR in 19% and medical treatment in 10%. The choice of TAVI over SAVR was associated with older age (P<0.0001) and a higher EuroSCORE II (P=0.008). However, the weight of EuroSCORE II in therapeutic decision making markedly decreased after the age of 80 years. Indeed, 77% of patients aged ≥ 80 years were referred for TAVI, despite a low estimated surgical risk.
CONCLUSIONS CONCLUSIONS
The impact of risk scores depends strongly on age, and decreases considerably after 80 years, most patients being referred for TAVI, independent of their estimated surgical risk. Despite medical advancements, 10% of patients were still denied any intervention.

Identifiants

pubmed: 34600866
pii: S1875-2136(21)00135-2
doi: 10.1016/j.acvd.2021.06.011
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

624-633

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Claire Bouleti (C)

CIC Inserm 1402, Cardiology Department, Poitiers University Hospital, Poitiers University, 2, rue de la Milétrie, 86000 Poitiers, France. Electronic address: claire.bouleti@gmail.com.

Morgane Michel (M)

ECEVE UMR 1123, Inserm, Hôpital Robert-Debré, URC Eco, Hotel-Dieu, AP-HP, 75019 Paris, France.

Antoine Jobbe Duval (A)

Nantes University Hospital, 44903 Nantes, France.

Thibaut Hemery (T)

Rouen University Hospital, 76000 Rouen, France.

Pierre-Philippe Nicol (PP)

Brest University Hospital, 29200 Brest, France.

Romain Didier (R)

Brest University Hospital, 29200 Brest, France.

Floriane Zeyons (F)

Strasbourg University Hospital, 67200 Strasbourg, France.

Oualid Zouaghi (O)

Clinique du Tonkin, 69100 Villeurbanne, France.

Didier Tchetche (D)

Clinique Pasteur, 31076 Toulouse, France.

Clémence Delon (C)

Toulouse University Hospital, 31059 Toulouse, France.

Maxence Delomez (M)

Polyclinique du Bois, 59000 Lille, France.

Alain Dibie (A)

Institut Mutualiste Montsouris, 75014 Paris, France.

David Attias (D)

Centre Cardiologique du Nord, 93200 Saint-Denis, France.

Hervé Le Breton (H)

Pontchaillou University Hospital, 35000 Rennes, France.

Bertrand Cormier (B)

Institut Cardiovasculaire Paris Sud, 91300 Massy, France.

Jean-François Obadia (JF)

Hôpital Cardiothoracique Louis-Pradel, 69500 Bron, France.

Christophe Tribouilloy (C)

Amiens University Hospital, 80054 Amiens, France.

Emmanuel Lansac (E)

Institut Mutualiste Montsouris, 75014 Paris, France.

Karine Chevreul (K)

ECEVE UMR 1123, Inserm, Hôpital Robert-Debré, URC Eco, Hotel-Dieu, AP-HP, 75019 Paris, France.

Nicole Naccache (N)

Commission des Registres, French Society of Cardiology, Paris, France.

Hélène Eltchaninoff (H)

Rouen University Hospital, 76000 Rouen, France.

Martine Gilard (M)

Brest University Hospital, 29200 Brest, France.

Bernard Iung (B)

Bichat Hospital, DHU Fire, Université de Paris, AP-HP, 75018 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH